Trial Profile
ASSessing the Effect of Anti-IL-6 Treatment in Myocardial Infarction: The ASSAIL-MI Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Myocardial infarction
- Focus First in man; Proof of concept; Therapeutic Use
- Acronyms ASSAIL-MI
- 20 Apr 2021 Primary endpoint (The primary endpoint will be the between-group difference in the myocardial salvage index as measured in the acute phase by cardiac magnetic resonance (CMR) imaging with late gadolinium enhancement (LGE).) has been met, as per results published in the Journal of the American College of Cardiology
- 20 Apr 2021 Results published in the Journal of the American College of Cardiology
- 28 Feb 2021 Status changed from active, no longer recruiting to completed.